Modular Medical shares surge 40.39% after-hours after validating Pivot controller line for Q1 2026 market launch.

Modular Medical (MODD) surged 40.39% in after-hours trading following the announcement of successful validation of its Pivot controller manufacturing line, a critical step toward its Q1 2026 commercial launch. The news underscored the company’s readiness for high-volume production of its tubeless, removable 3-milliliter patch pump, targeting the $3 billion market for adult “almost-pumpers.” The validation reduces manufacturing risks and positions Modular Medical to scale production efficiently, a key differentiator in the competitive insulin pump sector. The CEO emphasized the milestone aligns with the company’s goal to address an underserved patient segment with an affordable, user-friendly design. While regulatory clearance remains pending, the manufacturing progress signals operational execution and market potential, directly driving investor optimism in after-hours trading.